Gossamer Bio, Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Gossamer Bio announced on July 1, 2026, that its 7.50% Convertible Senior Secured First Lien Notes due 2030 will convert at 5,347.5936 shares per $1,000 principal (conversion price ~$0.19/share), and warrants will have an exercise price of $0.34/share. The reference price over the seven trading days ending June 22, 2026, was $0.17. These terms are formulaic adjustments based on the stock's trading price.
Why this rating
Administrative announcement of contractual conversion mechanics tied to reference price. No new capital raised, no counterparties named, no material financial event. Stock already reflects these terms at issuance; announcement is technical disclosure only.
Extracted items
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.